RNA-based therapeutics that prevent a key metabolic enzyme from being expressed in tumor-initiating cells (TIC) hold promise for the treatment of lung cancer, an A*STAR team has shown. As implied by their name, TIC – also known as cancer stem cells – are a subset of tumor cells with the capacity to self-renew and start new tumors. Abnormal metabolism is...